yemenjmedYemen Journal of MedicinecoVolume 1 Issue 1MultidisciplinaryEnglishJanuary - June 2022NNY20250325ArticleHemolytic uremic syndrome: An updated reviewEnglishY613Elmukhtar Habas1EnglishNAmnna Rayani2EnglishYAla Habas3EnglishYKalifa Farfar4EnglishYEshrakHabas3EnglishYAhmedElmarghani5EnglishYAbdel-NaserElzouki6EnglishY10.32677/yjm.v1i1.3346Hemolytic uremic syndrome (HUS) is a microangiopathic thrombotic disease, which is classified into atypical, typical, and secondary types. Thrombocytopenia, acute kidney failure, and hemolysis are the main features of HUS regardless of its type. Infection with Shiga toxin-producing Escherichia coli causes typical HUS, and gene mutations trigger atypical HUS, while secondary HUS is associated with bone marrow transplantation, autoimmunity, cancer, and other diseases. New insights into the pathogenesis of HUS have emerged over the past decades, suggesting an important role of the complement system in disease pathogenesis, which has been reinforced by the efficacy of plasma exchange and monoclonal antibodies in its treatment. In this review, we performed an updated review of HUS with a focus on understanding its pathogenesis.EnglishAtypical hemolytic uremic syndrome, Hemolysis, Hemolytic uremic syndrome, Renal impairment, Shiga toxin, Thrombocytopenia, Typical hemolytic uremic syndromehttps://www.yemenjmed.com/admin/abstract?id=4References16191.Arnold DM, Patriquin CJ, Nazy I. Thrombotic microangiopathies: A general approach to diagnosis and management. CMAJ 2017;189:E153-9.2. Land;auml;mmle B, Kremer Hovinga JA, et al. Thrombotic thrombocytopenic purpura. J Thromb Haemost 2005;3:1663-75.3. Tufano A, Coppola A, Maruotti GM, et al. HELLP syndrome and its relation with the antiphospholipid syndrome. Blood Transfus. 2014;12:114-8.4. Toh CH, Alhamdi Y, Abrams ST. Current pathological and laboratory considerations in the diagnosis of disseminated intravascular coagulation. Ann Lab Med 2016;36:505-12.5. Mathew RO, Nayer A, Asif A. The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy. J Am Soc Hypertens 2016;10:352-9.6. Rodrand;iacute;guez-Pintand;oacute; I, Espinosa G, Cervera R. Catastrophic APS in the context of other thrombotic microangiopathies. Curr Rheumatol Rep 2015;17:482.7. Woodworth TG, Suliman YA, Li W, et al. Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol 2016;12:678-91.8. Jokiranta TS. HUS and atypical HUS. Blood 2017;129:2847-56.9. Adams DA, Thomas KR, Jajosky RA, et al, Nationally Notifiable Infectious Conditions Group. Summary of notifiable infectious diseases and conditionsUnited States, 2015. MMWR Morb Mortal Wkly Rep 2017;64:1-143.10. Mukhopadhyay S, Linstedt AD. Manganese blocks intracellular trafficking of Shiga toxin and protects against Shiga toxicosis. Science 2012;335:332-5.11. Orth-Hand;ouml;ller D, Wand;uuml;rzner R. Role of complement in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Semin Thromb Hemost 2014;40:503-7.12. Grabowski EF, Kushak RI, Liu B, et al. Shiga toxin downregulates tissue factor pathway inhibitor, modulating an increase in the expression of functional tissue factor on endothelium. Thromb Res 2013;131:521-8.13. Karpman D, Manea M, Vaziri-Sani F, et al. Platelet activation in hemolytic uremic syndrome. Semin Thromb Hemost 2006;32:128-45.14. Arvidsson I, Stahl AL, Hedstrand;ouml;m MM, et al. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome. J Immunol 2015;194:2309-18.15. Amaral MM, Sacerdoti F, Jancic C, et al. Action of shiga toxin type-2 and subtilase cytotoxin on human microvascular endothelial cells. PLoS One 2013;8:e70431.16. Raina R, Krishnappa V, Blaha T, et al. Atypical hemolytic-uremic syndrome: An update on pathophysiology, diagnosis, and treatment. Ther Apher Dial 2019;23:4-21.17. Alhabhbeh A, Fatima Z, Thomas A, et al. Rare presentation of atypical hemolytic uremic syndrome in an adult. Cureus 2021;13:e18184.18. Sridharan M, Go RS, Willrich MA. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management. J Immunol Methods 2018;461:15-22.19. Cataland SR, Yang S, Wu HM. The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies. Br J Haematol 2012;157:501-3.20. Cataland SR, Wu HM. Diagnosis and management of complement mediated thrombotic microangiopathies. Blood Rev 2014;28:67-74.21. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010;5:1844-59.22. Fakhouri F, Hourmant M, Campistol JM, et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: A single-arm, open-label trial. Am J Kidney Dis 2016;68:84-93.23. Warwicker P, Goodship TH, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998;53:836-44.24. Nester CM, Barbour T, de Cordoba SR, et al. Atypical aHUS: State of the art. Mol Immunol 2015;67:31-42.25. de Cand;oacute;rdoba SR. Complement genetics and susceptibility to inflammatory disease. Lessons from genotype-phenotype correlations. Immunobiology 2016;221:709-14.26. Kielstein JT, Beutel G, Fleig S, et al, Collaborators of the DGfN STECHUS Registry. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: An analysis of the German STEC-HUS registry. Nephrol Dial Transplant 2012;27:3807-15.27. Allen U, Licht C. Pandemic H1N1 influenza A infection and (atypical) HUS--more than just another trigger? Pediatr Nephrol 2011;26:3-5.28. Sziland;aacute;gyi A, Kiss N, Bereczki C, et al. The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2013;28:2237-45.29. Berry AM, Lock RA, Paton JC. Cloning and characterization of nanB, a second Streptococcus pneumoniae neuraminidase gene, and purification of the NanB enzyme from recombinant Escherichia coli. J Bacteriol 1996;178:4854-60.30. Gottschalk A. The influenza virus neuraminidase. Nature 1958;181:377-8.31. Wehling C, Kirschfink M. Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: Requirement for comprehensive complement analysis. J Thromb Haemost 2014;12:1437-9.32. Bhakdi S, Tranum-Jensen J. C5b-9 assembly: Average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore. J Immunol 1986;136:2999-3005.33. Podack ER, Tschoop J, Muller-Eberhard HJ. Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assembly. J Exp Med 1982;156:268-82.34. Iida K, Whitlow MB, Nussenzweig V. Membrane vesiculation protects erythrocytes from destruction by complement. J Immunol 1991;147:2638-42.35. Laurence J. Atypical hemolytic uremic syndrome (aHUS): Making the diagnosis. Clin Adv Hematol Oncol 2012;10:1-12.36. Chien S. Red cell deformability and its relevance to blood flow. Annu Rev Physiol 1987;49:177-92.37. Canalejo K, Riera Cervantes N, Felippo M, et al. Paroxysmal nocturnal haemoglobinuria. Experience over a 10 years period. Int J Lab Hematol 2014;36:213-21.38. Karnchanaphanurach P, Mirchev R, Ghiran I, et al. C3b deposition on human erythrocytes induces the formation of a membrane skeleton-linked protein complex. J Clin Invest 2009;119:788-801.39. Moskovich O, Herzog LO, Ehrlich M, et al. Caveolin-1 and dynamin-2 are essential for removal of the complement C5b-9 complex via endocytosis. J Biol Chem 2012;287:19904-15.40. Sethi S, Fervenza FC. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost 2014;40:416-21.41. Manuelian T, Hellwage J, Meri S, et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 2003;111:1181-90.42. Huber-Lang M, Ignatius A, Brenner RE. Role of complement on broken surfaces after trauma. Adv Exp Med Biol 2015;865:43-55.43. Kang YH, Tan LA, Carroll MV, et al. Target pattern recognition by complement proteins of the classical and alternative pathways. Adv Exp Med Biol 2009;653:117-28.44. Gorsuch WB, Chrysanthou E, Schwaeble WJ, Stahl GL. The complement system in ischemia-reperfusion injuries. Immunobiology 2012;217:1026-33.45. Atkinson JP, Liszewski MK, Richards A, et al. Hemolytic uremic syndrome: An example of insufficient complement regulation on self-tissue. Ann N Y Acad Sci 2005;1056:144-52.46. Del Conde I, Crand;uacute;z MA, Zhang H, et al. Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005;201:871-9.47. Frimat M, Tabarin F, Dimitrov JD, et al. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood 2013;122:282-92.48. Hyvand;auml;rinen S, Meri S, Jokiranta TS. Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome. Blood 2016;127:2701-10.49. George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. Semin Thromb Hemost 2013;39:153-60.50. Atefi G, Aisiku O, Shapiro N, et al. Complement activation in trauma patients alters platelet function. Shock 2016;46:83-8.51. Martel C, Cointe S, Maurice P, et al. Requirements for membrane attack complex formation and anaphylatoxins binding to collagen-activated platelets. PLoS One 2011;6:e18812.52. Stahl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coliinduced hemolytic uremic syndrome. Blood 2011;117:5503-13.53. Tedesco F, Pausa M, Nardon E, et al. The cytolytically inactiveand;nbsp;terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 1997;185:1619-27.54. Oikonomopoulou K, Ricklin D, Ward PA, et al. Interactions between coagulation and complement--their role in inflammation. Semin Immunopathol 2012;34:151-65.55. Rinder CS, Rinder HM, Smith B, et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 1995;96:1564-72.56. Wiedmer T, Esmon CT, Sims PJ. Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase. Blood 1986;68:875-80.57. Sims PJ, Wiedmer T. Repolarization of the membrane potential of blood platelets after complement damage: Evidence for a Ca++ -dependent exocytotic elimination of C5b-9 pores. Blood 1986;68:556-61.58. Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000;342:1930-6.59. McGannon CM, Fuller CA, Weiss AA. Different classes of antibiotics differentially influence Shiga toxin production. Antimicrob Agents Chemother 2010;54:3790-8.60. Michael M, Elliott EJ, Ridley GF, et al. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database Syst Rev 2009;2009:CD003595.61. Johnson S, Taylor CM. Whatand;rsquo;s new in haemolytic uraemic syndrome? Eur J Pediatr 2008;167:965-71.62. Wehling C, Amon O, Bommer M, et al. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol 2016;187:304-15.63. Cornec-Le Gall E, Delmas Y, De Parscau L, et al. Adult-onset eculizumabresistant hemolytic uremic syndrome associated with cobalamin C deficiency. Am J Kidney Dis 2014;63:119-23.64. Fakhouri F, Fila M, Hummel A, et al. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: A prospective multicenter study. Blood 2021;137:2438-49.65. Ultomiris (ravulizumab) Package Insert. Boston, MA: Alexion Pharmaceuticals, Inc.; 2019.